A new finding questions the usefulness of some mouse models.
Treatments that promote neurogenesis and elevate BDNF act as exercise does to improve memory in mouse models of Alzheimer’s disease.
Computational models predict that ALS mutations tax the flexibility of profilin-1, weaken binding with key partners including actin, and boost the protein’s propensity to aggregate.
By yanking a nuclear protein out of its pore, phosphorylated tau makes nuclei leaky, disrupting the strictly controlled passage of proteins and setting tau up for aggregation.
PET tracer predicts tau pathology and AD, according to company press release.
Study links changes in the retina’s microvasculature to brain amyloid in cognitively normal adults.
Loss-of-function mutations in TBK1 combined with age-related dearth of an analog spell trouble for motor neurons and the central nervous system.
A molecular-level view of tau filaments from a person with Pick’s disease reveals that the protein folds up differently than it does in Alzheimer’s disease.
Vascular microchannels linking the skull bone marrow to the dura mater supply the brain with neutrophils in response to stroke and inflammation.
AAIC showcased advances in scientists’ attempts to integrate technology into dementia care and research. This includes the use of furry robot seals to keep patients company.
The microfluidic device could test the vascular contributions to neurodegenerative disease and bioavailability of drugs for the brain.
What's the use of measuring neurofilament light in blood? The marker could help with AD trial enrollment and measuring drug effects. It could even guide brain-sparing improvements in heart surgery, say researchers at AAIC 18.
With buckets of new data at AAIC, blood NfL grabbed attention as a telltale of neurodegeneration. The protein predicts progression, and might one day track treatment effects.
The dopamine receptor agonist ropinirole emerged as the top hit in a screen of induced motor neurons.
The 2019 budget ups this year’s spending by $425 million.